Red Rock Resorts earnings beat by $0.54, revenue topped estimates
In a challenging market environment, Ziff Davis, Inc. (formerly known as j2 Global (NASDAQ:ZD)) saw its stock price touch a 52-week low, dipping to $32. According to InvestingPro analysis, the company maintains impressive gross profit margins of 85.7% and shows signs of being undervalued based on its Fair Value metrics. This latest price level reflects a significant downturn for the company, which has experienced a 1-year change with a sharp decline of 41.72%. Investors are closely monitoring Ziff Davis as it navigates through the headwinds that have pressured the stock to its current low, seeking signs of a potential rebound or further indicators of market adversity. The company's performance is being scrutinized as stakeholders consider the broader economic factors at play and the firm's strategic responses. InvestingPro data reveals the stock is trading at attractive levels relative to its earnings growth potential, with 15 additional ProTips available to subscribers analyzing the company's financial health and market position.
In other recent news, Ziff Davis Inc. reported its financial results for Q4 2024, showing an adjusted diluted earnings per share (EPS) of $2.58, slightly above the forecast of $2.57. However, the company missed revenue expectations, reporting $412.8 million against the anticipated $423.87 million. This mixed performance was noted during the company's earnings call, where they also highlighted a 5.9% year-over-year revenue increase for the quarter. Additionally, Ziff Davis's Everyday Health Group announced the acquisition of digital media company theSkimm, aiming to expand its reach in women's health and wellness content.
In other developments, Citi analysts adjusted their outlook on Ziff Davis, reducing the price target from $58.00 to $52.00 while maintaining a Neutral rating. The adjustment followed a review of Ziff Davis's fourth-quarter results and full-year 2025 guidance, which showed both progress and ongoing challenges. Analysts noted potential risks from GenAI Search but acknowledged the company's current valuation as attractive. Management expressed confidence in a return to growth across all segments in 2025, despite the first quarter being anticipated as weaker.
The acquisition of theSkimm is expected to enhance Everyday Health Group's offerings, tapping into theSkimm's audience for more comprehensive health information. The terms of the acquisition were not disclosed, and Wolfson Partners LLC acted as the financial advisor for theSkimm during the transaction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.